Simple HealthKit

-72%

est. 2Y upside i

HealthcareSeries B

Simple HealthKit is addressing health inequity with the first human-centric, complete diagnostics platform that includes access to follow-up care for sexual wellness, respiratory health and chronic co

Rank

#3254

Sector

Healthcare

Est. Liquidity

~3Y

Data Quality

Data: Medium

Simple HealthKit presents a moderate upside opportunity for a job seeker, with an estimated 20.5% expected return over a two-year horizon.

Last updated: March 10, 2026

Bull (10%)+250%

Simple HealthKit significantly expands its partnerships with major retailers and health plans, leveraging its end-to-end platform and CLIA-certified labs to capture a larger share of the rapidly growing home diagnostics and digital health markets. Revenue accelerates to over $150M by 2028, justifying a $700M+ valuation (3.5x current estimate) as it proves its ability to scale efficiently despite incumbent competition.

Base (45%)+50%

The company maintains its current growth trajectory, expanding partnerships and product offerings at a steady pace. It carves out a niche in the competitive landscape but faces ongoing pressure from larger incumbents. Revenue reaches approximately $60M-$70M by 2028, leading to a modest valuation increase to around $300M (1.5x current estimate) in an acquisition or later funding round.

Bear (45%)-60%

Dominant incumbents like Quest Diagnostics or Amazon/Walmart aggressively expand their own at-home diagnostic and digital health offerings, commoditizing Simple HealthKit's services and eroding its market share. Regulatory hurdles or slower-than-expected adoption of new programs lead to stagnant growth. The company struggles to raise further capital, resulting in a down round or distressed acquisition at a valuation of $80M or less, significantly impacting common stock value due to liquidation preferences.

Est. time to liquidity~3.0 years

Preference Stack Risk

moderate

Investors hold $25M in liquidation preferences ahead of common stock. In an exit at or below $25M, common stock would receive nothing. In an exit at the estimated current valuation of $200M, $175M would be available for common shareholders.

Dilution Risk

moderate

As a Series B company, Simple HealthKit will likely require additional funding rounds (Series C, D) before a liquidity event, which will lead to further dilution for existing equity holders.

Secondary Liquidity

none

There is no indication of active secondary markets or tender offers for Simple HealthKit's equity at this time.

Questions to Ask at the Interview

Strategic questions based on Simple HealthKit's data — designed to show you've done your homework.

1
“Given the strategic partnerships with Amazon and Walmart, how does Simple HealthKit plan to navigate the potential for these large incumbents to expand their own in-house diagnostic and digital health services, which could directly compete with your offerings?”
2
“With a weighted growth rate of approximately 13% YoY, what are the key initiatives or new product lines that the company believes will significantly accelerate revenue growth beyond this rate in the next 2-3 years?”
3
“Considering the Series B funding round in late 2024, what is the anticipated timeline for a liquidity event (e.g., acquisition or IPO) for employees, and how is the company managing potential future dilution from additional funding rounds?”

Community

Valuation Sentiment

Our model estimates -72% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.